Levo-Leucovorin

Phase 3Small molecule

Levo-Leucovorin is one of 79 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Camptosar

EEastern Cooperative Oncology Group

Phase 3

5 2

Docetaxel Micellar

Sanofi

Phase 3

1 3

Levo-Leucovorin

Pfizer

Phase 3

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06793917

Clinical

Trials by Indication[1]

Tislelizumab1 trial

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05319639·51 enrolled

Gastric Cancer1 trial

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT06197438·36 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·FFujian Cancer Hospital·Phase 3·NCT06793917·269 enrolled

Metastatic Colorectal Cancer1 trial

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00457691·768 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Levo-Leucovorin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levo-Leucovorin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levo-Leucovorin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Levo-Leucovorin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Tislelizumab1 trial

Gastric Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News